Altavant – Page 2 – Sumitovant

April 15, 2021Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
April 12, 2021Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
April 12, 2021Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
March 29, 2021Sumitovant Biopharma Completes Acquisition of Urovant Sciences
March 26, 2021Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
March 02, 2021Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation
February 18, 2021Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
February 17, 2021Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
February 12, 2021Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
February 11, 2021Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
« Previous 1 2 3 4 … 17 Next »